Wolfe Research Raises Gilead Sciences Price Target to $170 on HIV Franchise Strength

Wolfe Research has increased its price target for Gilead Sciences (GILD) to $170 from the previous $155, while reiterating its "Outperform" rating. The upward revision is driven by the anticipated robust performance of the company's HIV drug portfolio heading into 2025. Analysts specifically highlighted the growth potential of key products such as Descovy and Yeztugo as primary drivers within the HIV segment. Looking ahead, the research firm forecasts a strong fiscal year 2026, with earnings per share (EPS) expected to reach $8.76. While potential U.S. policy headwinds remain a consideration, the long-term outlook for Gilead’s core business remains positive. This adjustment reflects growing investor confidence in the biotechnology giant's ability to maintain its market leadership in infectious diseases.